Papers - MATSUURA Motoki

当科における卵巣組織凍結の現状報告と北海道における小児科医の卵巣組織凍結に対する意識調査

古来 愛香, 玉手 雅人, 春日 芙貴子, 長尾 沙智子, 西村 庸子, 松浦 基樹, 久野 芳佳, 馬場 剛, 齋藤 豪

日本がん・生殖医療学会誌 ( (一社)日本がん・生殖医療学会 )  6 ( 1 ) 49 - 53  2023.02

　View Summary

【緒言】小児・思春期・若年成人(children,adolescents and young adults:C-AYA)世代のがんサバイバーが増加することにともない、QOL向上の意識が高まり妊孕性温存法も発展しつつある。当科では、小児がん患者の卵巣組織凍結保存を実施してきた。今回、当院での卵巣組織凍結保存の現状報告(研究1)、および北海道内の小児科医における卵巣組織凍結に対する意識調査(研究2)について報告する。【対象と方法】研究1:2012年12月～2021年6月までに当科で卵巣組織凍結保存を目的とした卵巣摘出術手術20例を対象に、年齢、原疾患、コンサルトから手術までの期間、周術期経過、合併症などの背景を集積した。研究2:北海道内の悪性疾患を診療する小児科医に卵巣組織凍結の認識を匿名でアンケート調査した。【結果】研究1:初診時平均年齢は18.8±8.49歳。原疾患は、血液腫瘍13例、脳腫瘍3例、乳癌2例、軟部腫瘍2例であった。手術までの期間は3-99日(平均31.5±21.5日)、全例腹腔鏡手術であった。研究2:アンケートは5施設18名から回収した。卵巣組織凍結について認識している人が18名(100%)、情報提供をしたことがある人が13名(72.2%)であった。卵巣組織凍結の情報提供をしたが治療の同意が得られない理由としては、経済的理由(保険適応外)、手術のリスク、原疾患治療の遅れ、エビデンスが乏しい、などがあげられた。【結語】卵巣組織凍結保存は微小残存がん病巣(MRD:minimal residual disease)のリスクがあるが、月経発来前の女児に対して唯一の妊孕性温存療法である。しかし、社会的要因によって普及には至っていない。今後、凍結卵巣融解移植成績の発信や卵巣組織凍結の説明方法の均てん化などにより一層卵巣組織凍結という選択肢を提示していきたい。症例治療が滞りなく円滑に進むよう、主治医、生殖医、婦人科腫瘍医の連携が重要であり、今後尽力したい。(著者抄録)

Concurrent lung adenocarcinoma hidden among multiple shadows of COVID-19 pneumonia: A rare and instructive case report.

Yoshihiro Kitahara, Motoki Matsuura, Rie Yamasaki, Kanako Nakamoto, Shinji Kakumoto, Shinpei Tada, Noriaki Ito, Kei Miwata, Mafumi Okimoto, Toshiro Takafuta

Clinical case reports   11 ( 2 ) e6859  2023.02  [International journal]

　View Summary

A 40-year-old man was admitted with a diagnosis of COVID-19 pneumonia. Although most of multiple ground-glass opacities and consolidations on computed tomography improved, a round ground-glass opacity with consolidation remained unchanged and was suspected to be a part-solid nodule of lung adenocarcinoma. Pathologic diagnosis of resected tumor was papillary adenocarcinoma.

DOI PubMed

深層学習を用いたHE染色からの子宮内膜癌分子生物学的プロファイル推定の適否に関する検討

梅本 美菜, 真里谷 奨, 新開 翔太, 松浦 基樹, 岩崎 雅宏, 齋藤 豪

日本産科婦人科学会雑誌 ( (公社)日本産科婦人科学会 )  75 ( 臨増 ) S - 260  2023.02

A mixed-method evaluation of cadaver surgery training for gynecologic oncology.

Masato Tamate, Motoki Matsuura, Hiroyuki Kanao, Tsuyoshi Saito

The journal of obstetrics and gynaecology research   48 ( 12 ) 3252 - 3261  2022.12  [International journal]

　View Summary

AIM: Traditional surgical training techniques with using patients, and new advances with live animals, artificial models, and simulation methods have several shortcomings. There are a few reports on the usefulness of cadaver surgery training (CST) in gynecology. Herein, we used a mixed-method evaluation to qualitatively and quantitatively explore the educational efficacy of CST by conducting CST programs at the Sapporo Medical University, Japan. METHODS: In 2020, we conducted two CST programs with 45 participants-13 residents, 8 specialists recognized by Japan Society of Obstetrics and Gynecology, 23 certified endoscopists recognized by Japan Society of Gynecology and Obstetrics Endoscopy and Minimally Invasive Therapy, 15 specialists recognized by Japan Society of Gynecologic Oncology, and 14 certified endoscopists cum oncology. Three participants observed the procedure virtually and 42 were physically present. Laparoscopic radical hysterectomy and pelvic exenteration were performed on five Thiel-embalmed cadavers. Participants were asked to complete pre- and post-training surveys that included qualitative questions, concerning the purpose and cost of CST, and quantitative questions, testing anatomical knowledge. RESULTS: We observed that the rate of score improvement to the quantitative questions increased from 58.6% pre-CST to 75.6% post-CST. Furthermore, oncology specialists and those who performed more surgeries and faced more complications during surgeries recorded high percentage of correct answers. Multiple regression analysis statistically confirmed these results. CONCLUSIONS: This study confirmed the educational efficacy of CST.

DOI PubMed

vNOTESによる膜解剖理論に基づいた直腸周囲展開

足立 岳貴, 松浦 基樹, 黒川 晶子, 西村 庸子, 玉手 雅人, 秋元 太志, 齋藤 豪

日本内視鏡外科学会雑誌 ( (一社)日本内視鏡外科学会 )  27 ( 7 ) 599 - 599  2022.12

Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy.

Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoh Kozuka, Masashi Idogawa, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-Ichi Sakata

Medical molecular morphology   56 ( 1 ) 38 - 45  2022.11  [Domestic journal]

　View Summary

Resistance of cervical cancer to radiotherapy with concurrent chemotherapy (CCRT) results in a poor prognosis. To identify new biomarkers for predicting the treatment response and prognosis, we explored exosomal microRNA (miRNA) expression signatures associated with the outcome of cervical cancer patients treated with CCRT. Exosomes were isolated from the plasma of 45 patients prior to CCRT during 2014-2020, and miRNA analysis was performed by next-generation sequencing. At a median follow-up of 38 months, 26 patients were recurrence free, 15 patients had died of the disease, and 4 patients received salvage chemotherapy due to distant metastasis. Of the 2522 miRNAs detected, 9 (miR-148a-5p, 1915-3p, 3960, 183-5p, 196b-5p, 200c-3p, 182-5p, 374a-5p, and 431-5p) showed differential expression between the recurrence-free and recurrence groups. Patients were divided into high- and low-risk groups according to the cutoff of the miRNAs-based risk score calculated from respective expression levels. The high-risk group had significantly worse disease-specific survival than the low-risk group (p < 0.001). In addition, miR-374a-5p and miR-431-5p expression showed a weak inverse correlation with tumor-infiltrating CD8+ and FOXP3+ T cells, suggesting a potential inhibitory effect on CCRT by suppressing tumor immunity. This miRNA signature could improve non-invasive monitoring and personalized treatment for cervical cancer.

DOI PubMed

Human papillomavirus testing and cytology using physician-collected uterine cervical samples vs. self-collected vaginal samples and urine samples.

Noriko Terada, Motoki Matsuura, Shoko Kurokawa, Yoko Nishimura, Masato Tamate, Kyoko Isoyama, Satoko Yamazaki, Hiroshi Shimada, Masahiro Suzuki, Yuta Tabuchi, Mizue Teramoto, Tsuyoshi Saito

International journal of clinical oncology   27 ( 11 ) 1742 - 1749  2022.11  [Domestic journal]

　View Summary

BACKGROUND: Human papillomavirus (HPV) testing using self-collected vaginal samples and urine samples is convenient and effective for improving the screening rate. But, to serve as an alternative cervical cancer screening technique, such tests must offer sensitivity equivalent to the HPV testing of physician-collected cervical samples. To examine the effectiveness of HPV testing using self-collected samples and urine samples, we compared the results of HPV testing using these samples with those of HPV testing using physician-collected samples and cytological examinations. METHODS: The study population included 300 women (age: 20-50 years) with abnormal cervical cytology. The results of HPV testing using self-collected samples and urine samples and physician-collected samples and cervical cytology were compared. RESULTS: For all HPV types, the κ-value was 0.773 for physician- and self-collected samples and 0.575 for physician-collected and urine samples. The κ-value for HPV type 16-positive samples was 0.988 for physician- and self-collected samples and 0.896 for physician-collected and urine samples. The κ-value for HPV type 18-positive samples was 0.856 for physician- and self-collected samples and 0.831 for physician-collected and urine samples. For other HPV types, the value was 0.809 for physician- and self-collected samples and 0.617 for physician-collected and urine samples. CONCLUSIONS: The obtained results were consistent between physician- and self-collected samples as well as between physician-collected and urine samples. Considering that the agreement rate was particularly high for the high-risk HPV types 16 and 18, HPV testing using physician-collected samples, self-collected samples, and urine samples was equally effective for the types with high carcinogenicity.

DOI PubMed

子宮移植/妊娠中免疫抑制療法/胎児免疫 Thiel法固定献体における子宮移植トレーニング

玉手 雅人, 松浦 基樹, 木須 伊織, 齋藤 豪

Organ Biology ( (一社)日本臓器保存生物医学会 )  29 ( 3 ) 86 - 86  2022.11

血中エクソソーム由来miRNAを用いた子宮頸癌の治療効果予測

染谷 正則, 土屋 高旭, 福島 悠希, 長谷川 智一, 井戸川 雅史, 松浦 基樹, 岩崎 雅宏, 廣橋 良彦, 鳥越 俊彦, 齋藤 豪, 坂田 耕一

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  60回   P102 - 2  2022.10

子宮悪性軟部腫瘍に対する新規薬剤が効果を認めた症例の検討

萬 和馬, 松浦 基樹, 足立 岳貴, 有元 千紘, 黒川 晶子, 西村 庸子, 玉手 雅人, 秋元 太志, 幅田 周太朗, 岩崎 雅宏, 齋藤 豪

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  60回   O46 - 2  2022.10

子宮頸がん検診未受診者対策としての自己採取HPV検査の有効性評価

松浦 基樹, 寺田 倫子, 西村 庸子, 玉手 雅人, 長尾 沙智子, 秋元 太志, 幅田 周太朗, 岩崎 雅宏, 齋藤 豪

日本臨床細胞学会雑誌 ( (公社)日本臨床細胞学会 )  61 ( Suppl.2 ) 477 - 477  2022.10

子宮動脈塞栓術併用の子宮鏡下切除術において子宮内バルーニングが有用であったRPOCの一例

南 怜毅, 長尾 沙智子, 木嶋 紗弓, 小川 栞, 山崎 智子, 玉手 雅人, 松浦 基樹, 齋藤 豪

北日本産科婦人科学会総会・学術講演会プログラム・抄録集 ( 東北連合産科婦人科学会・北日本産科婦人科学会 )  69回   64 - 64  2022.10

巨大嚢胞化し、子宮留膿腫を繰り返した帝王切開瘢痕部症候群の1例

仁木 舜一, 嶋田 浩志, 玉手 雅人, 杉山 芽, 今 沙織, 鈴木 美紀, 松浦 基樹, 齋藤 豪

北日本産科婦人科学会総会・学術講演会プログラム・抄録集 ( 東北連合産科婦人科学会・北日本産科婦人科学会 )  69回   112 - 112  2022.10

巨大嚢胞化し、子宮留膿腫を繰り返した帝王切開瘢痕部症候群の1例

仁木 舜一, 嶋田 浩志, 玉手 雅人, 杉山 芽, 今 沙織, 鈴木 美紀, 松浦 基樹, 齋藤 豪

北日本産科婦人科学会総会・学術講演会プログラム・抄録集 ( 東北連合産科婦人科学会・北日本産科婦人科学会 )  69回   112 - 112  2022.10

子宮動脈塞栓術併用の子宮鏡下切除術において子宮内バルーニングが有用であったRPOCの一例

南 怜毅, 長尾 沙智子, 木嶋 紗弓, 小川 栞, 山崎 智子, 玉手 雅人, 松浦 基樹, 齋藤 豪

北日本産科婦人科学会総会・学術講演会プログラム・抄録集 ( 東北連合産科婦人科学会・北日本産科婦人科学会 )  69回   64 - 64  2022.10

LSR antibody promotes apoptosis and disrupts epithelial barriers via signal pathways in endometrial cancer.

Kimihito Saito, Takumi Konno, Takayuki Kohno, Hiroshi Shimada, Motoki Matsuura, Tadahi Okada, Arisa Kura, Daichi Ishii, Masuo Kondoh, Tsuyoshi Saito, Takashi Kojima

Tissue barriers     2106113 - 2106113  2022.07  [International journal]

　View Summary

Lipolysis-stimulated lipoprotein receptor (LSR), a lipid metabolism-related factor localized in tricellular tight junctions (tTJs), plays an important role in maintaining the epithelial barrier. LSR is highly expressed in well-differentiated endometrial endometrioid carcinoma (EEC), and its expression decreases during malignancy. Angubindin-1, a novel LSR ligand peptide, regulates tTJs without cytotoxicity, enhances paracellular permeability, and regulates epithelial barrier via c-Jun N-terminal kinase (JNK)/cofilin. In this study, we investigated the immune-modulatory roles of an anti-LSR antibody in the treatment of EEC in vitro compared to those of angubindin-1. We prepared an antibody against the extracellular N-terminal domain of human LSR (LSR-N-ab) and angubindin-1. EEC cell-line Sawano cells in 2D and 2.5D cultures were treated with 100 μg/ml LSR-N-ab or 2.5 μg/ml angubindin-1 with or without protein tyrosine kinase 2β inhibitor PF431396 (PF43) and JNK inhibitor SP600125 (SP60) at 10 μM. Treatment with LSR-N-ab and angubindin-1 decreased LSR at the membranes of tTJs and the activity of phosphorylated LSR and phosphorylated cofilin in 2D culture. Treatment with LSR-N-ab and angubindin-1 decreased the epithelial barrier measured as TEER values in 2D culture and enhanced the epithelial permeability of FD-4 in 2.5D culture. Treatment with LSR-N-ab, but not angubindin-1, induced apoptosis in 2D culture. Pretreatment with PF43 and SP60 prevented all the changes induced by treatment with LSR-N-ab and angubindin-1. Treatment with LSR-N-ab and angubindin-1 enhanced the cell metabolism measured as the mitochondrial respiration levels in 2D culture. LSR-N-ab and angubindin-1 may be useful for therapy of human EEC via enhanced apoptosis or drug absorption.

DOI PubMed

Pathological classification of desmoplastic reaction is prognostic factor in cervical adenocarcinoma.

Taishi Akimoto, Akira Takasawa, Kumi Takasawa, Tomoyuki Aoyama, Motoki Matsuura, Masato Tamate, Masahiro Iwasaki, Shutaro Habata, Taro Murakami, Makoto Osanai, Tsuyoshi Saito

Medical molecular morphology   55 ( 4 ) 275 - 282  2022.07  [Domestic journal]

　View Summary

Desmoplastic reaction (DR) and inflammation are significant pathological manifestations of tumorigenesis in several cancers. However, the correlation between these stromal reactions and cervical adenocarcinoma has been poorly documented. This investigation elucidated whether DR is a prognostic indicator in early cervical adenocarcinoma patients. Fifty-nine patients with early stage cervical adenocarcinoma (stages I/II) were included in the study. DR was divided into three groups, mature, intermediate, and immature, based on the presence of myxoid stroma and hyalinized keloid-like collagen. Inflammatory cell responses were classified as mild, moderate, and severe. Those stromal reactions were separately evaluated in the invasion front stroma and intratumoral stroma. In both the intratumor and invasion front stroma, intermediate/immature DR was correlated with tumor size, T stage, N stage, lymphovascular invasion, and parametrial infiltration (p < 0.001 to p < 0.05). In addition, in the intratumoral stroma, intermediate/immature DR led to short relapse-free survival and overall survival (p < 0.001). In the invasion front stroma, inflammatory cell responses were associated with DR immaturity and FIGO stage (p < 0.01). These results suggest that the classification of DR maturity is a potential prognostic biomarker in early stage cervical adenocarcinoma patients. DR can be evaluated by routine H&E staining without immunohistochemistry, making it convenient and economical in clinical practice.

DOI PubMed

プラチナ感受性再発卵巣がんに対するオラパリブ,ニラパリブ維持療法の比較検討

有元 千紘, 松浦 基樹, 足立 岳貴, 萬 和馬, 和田 渚, 篠原 由梨, 黒川 晶子, 西村 庸子, 玉手 雅人, 磯山 響子, 秋元 太志, 幅田 周太朗, 岩崎 雅宏, 齋藤 豪

日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  64回   273 - 273  2022.07

当院における早期子宮体癌再発症例の検討

幅田 周太朗, 岩崎 雅宏, 萬 和馬, 野藤 五沙, 玉手 雅人, 秋元 太志, 松浦 基樹, 齋藤 豪

日本婦人科腫瘍学会学術講演会プログラム・抄録集 ( (公社)日本婦人科腫瘍学会 )  64回   246 - 246  2022.07

Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s).

Mitsutake Yano, Kaei Nasu, Masanori Yasuda, Tomomi Katoh, Masahiro Kagabu, Hisanori Kobara, Motoki Matsuura, Osamu Tokuyama, Takaharu Yamawaki, Senn Wakahashi, Tomoko Noguchi, Kaoruko Mizuno, Keiji Shitsukawa, Yoshimasa Onohara, Takashi Nakabori, Aki Miyasaka, Takehiro Nakao, Tatsuya Matsunaga, Yusuke Kunimi, Manabu Sakurai, Aya Uchiyama, Ryoji Itoh, Nobuyuki Ohike, Takashi Hirakawa, Tadashi Watanabe, Koji Nishino, Takashi Motohashi, Kimihiko Ito

Melanoma research   32 ( 3 ) 150 - 158  2022.06  [International journal]

　View Summary

The objective of this study was to propose prognostic factors and optimal treatment strategies by analyzing the clinicopathological features and programmed death-ligand 1 (PD-L1) expression. We analyzed 31 patients diagnosed with uterine or ovarian melanoma between 1997 and 2017 in the Kansai Clinical Oncology Group/Intergroup. Twenty-four and seven patients with cervical and ovarian melanomas were included, respectively. Immune checkpoint inhibitors were used in seven patients, and the objective response rate was 40%. Notably, two patients with objective responses had a high PD-L1 expression. Ten and four patients with cervical and ovarian melanomas, respectively, had high PD-L1 immunohistochemical expressions. Multivariate analysis revealed that tumor stage was an independent prognostic factor for progression-free survival in patients with cervical melanomas. In patients with ovarian melanomas, the 1-year cumulative progression-free and overall survival rates were 0 and 29%, respectively. Kaplan-Meier analyses revealed that age <60 years was associated with poorer progression-free and overall survivals in patients with ovarian melanomas. In patients with cervical melanomas, the 1-, 3-, and 5-year cumulative overall survival rates were 53, 32, and 16%, respectively. Histological atypia was associated with a poorer progression-free survival, but there was no difference in survival between patients who underwent radical hysterectomy and those who did not. The present study is a large cohort study of uterine and ovarian melanomas, which are aggressive tumors with a significantly poor prognosis, even after standard surgery and adjuvant therapy. The use of immune checkpoint inhibitors is a promising and effective treatment option.

DOI PubMed